GS-3242

Phase 1Small molecule

Gilead

GS-3242 is one of 11 small molecule programs targeting HIV-1. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

HIV-1Recruiting

HIV-1Phase 1

Recruiting

Competition

Competitive Landscape

11 competitors in HIV-1

#DrugCompanyPhaseTrials

Cabenuva

GSK

Approved

4 2

Biktarvy

Gilead

Phase 3

3 3

Sunlenca

Gilead

Phase 3

1 4

B/F/TAF

Gilead

Phase 3

2 5

ISL/LEN

Gilead

Phase 3

1 6

VRC07-523LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

2 7

IM CAB LA

GSK

Phase 2

1 8

PGT121.414.LS

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 1

1 9

GS-3242

Gilead

Phase 1

1 10

Thymopentin

IImmunobiology Research Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

HIV-1

NCT07001319

Clinical

Trials by Indication[1]

HIV-11 trial

Study of GS-3242 in Participants With HIV-1; Substudy-05

Recruiting· Gilead logo

Gilead·Phase 1·NCT07001319·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for GS-3242. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GS-3242 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GS-3242. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Gilead

GS-3242

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

HIV-11 trial

References

Drug Info

Quick Facts

Related News